Answers are grounded in this paper and cite their sources.
The anticancer properties of Vitamin C (ascorbic acid o sodium ascorbate) are known since at least four decades, , being a cheap and "natural" product, Vitamin C is not patentable and therefore has never been developed an anticancer molecule. in vitro investigations have confirmed the extraordinary antitumor properties of high doses of Vitamin C (sodium ascorbate), particularly when administered by the intravenous route, and phase I/II randomized, controlled trials have been started to verify its anticancer properties in vivo. , the controlled clinical trials performed so far, do not confirm the extraordinary results obtained with C (sodium ascorbate) in vitro. However, this may depend on a number of different factors, such as the preparation (Sodium ascorbate may be more suitable than buffered ascorbic acid), the schedule of (slow infusion better than rapid infusion), tumor tissue oxygenation (Cancer tissue oxygenation is that oxygenation of tumor cell lines, in vitro), etc., which deserve further in depth investigation. with these limitations, Vitamin C (sodium ascorbate) in high doses, administered by intravenous route, being extremely effective in vitro, against a number of human tumor cell lines, is safe, has minimal , improves the quality of life of patients, and is highly selective for cancer cells. Authors discuss these important aspects and suggest possible solutions to improve the in vivo anticancer of Vitamin C (sodium ascorbate).
No takes yet. Share an insight, caveat, or question.
Mastrangelo et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: